Affiliation:
1. From US Oncology Research Inc, Houston, TX; Departments of Oncology and Medicine, McGill University, Montreal, Quebec, Canada; Rush-Presbyterian-St Luke's Medical Center, Chicago; Loyola University Medical Center, Maywood, IL; and the University of California, Los Angeles, School of Medicine,Los Angeles, CA
Abstract
Purpose This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab and paclitaxel with or without carboplatin as first-line therapy for women with HER-2–overexpressing metastatic breast cancer (MBC). Patients and Methods HER-2 overexpression was defined as immunohistochemical staining scores of 2+ or 3+. Between November 1998 and May 2002, 196 women with HER-2–overexpressing MBC were randomly assigned to six cycles of either trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclitaxel 175 mg/m2 every 3 weeks (TP), or trastuzumab 4 mg/kg loading dose plus 2 mg/kg weekly thereafter with paclitaxel 175 mg/m2 and carboplatin area under the time-concentration curve = 6 every 3 weeks (TPC) followed by weekly trastuzumab alone. Results Baseline characteristics of the 196 patients were well balanced between study arms. Objective response rate (ORR) was 52% (95% CI, 42% to 62%) for TPC versus 36% (95% CI, 26% to 46%) for TP (P = .04). Median progression-free survival (PFS) was 10.7 months for TPC and 7.1 months for TP (hazard ratio [HR], 0.66; 95% CI, 0.59 to 0.73; P = .03). Improved clinical outcomes with TPC were most evident in HER-2 3+ patients, with an ORR of 57% (95% CI, 45% to 70%) v 36% (95% CI, 25% to 48%; P = .03) and median PFS of 13.8 v 7.6 months (P = .005) for TPC and TP, respectively (HR, 0.55; 95% CI, 0.46 to 0.64). Both regimens were well tolerated, and febrile neutropenia and neurotoxicity occurred infrequently; grade 4 neutropenia occurred more frequently with TPC (P < .01). Conclusion The addition of carboplatin to paclitaxel and trastuzumab improved ORR and PFS in women with HER-2–overexpressing MBC. This well-tolerated regimen represents a new therapeutic option.
Publisher
American Society of Clinical Oncology (ASCO)
Reference28 articles.
1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/
neu
Oncogene
2. Studies of the HER-2/
neu
Proto-Oncogene in Human Breast and Ovarian Cancer
3. Owens MA, Horten BC, DaSilva MM: Correlation of HER-2/neu immunohistochemistry with fluorescence in situ hybridization in 3568 breast cancers. Breast Cancer Res Treat 76:S68,2002 (abstr 236),
4. Press MF, Sauter G, Bernstein L, et al: Comparison of HER-2/neu status determined by fluorescence in situ hybridization (FISH) in the BCIRG central laboratories with HER-2/neu status determined by immunohistochemistry or FISH in outside laboratories. Breast Cancer Res Treat 76:S69,2002 (abstr 238),
5. Association of C-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
Cited by
426 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献